News | January 03, 2022
U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
A toll-free helpline to be set up to help doctors and patients
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Subscribe To Our Newsletter & Stay Updated
